

Hetty E Carraway

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/115467/publications.pdf>

Version: 2024-02-01

225
papers

4,846
citations

134610

34
h-index

111975

67
g-index

226
all docs

226
docs citations

226
times ranked

7873
citing authors

#	ARTICLE	IF	CITATIONS
1	Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. <i>Leukemia</i> , 2021, 35, 1023-1036.	3.3	62
2	Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , 2021, 62, 735-738.	0.6	5
3	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. <i>Leukemia</i> , 2021, 35, 3324-3328.	3.3	2
4	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. <i>Blood</i> , 2021, 137, 3685-3689.	0.6	50
5	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1885-1895.	0.6	32
6	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. <i>JCI Insight</i> , 2021, 6, .	2.3	12
7	Current and emerging strategies for management of myelodysplastic syndromes. <i>Blood Reviews</i> , 2021, 48, 100791.	2.8	34
8	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 917.e1-917.e9.	0.6	3
9	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory) Tj ETQq1 1 0.784314 rgBT /Over	0.6	1
10	Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. <i>Leukemia</i> , 2021, 35, 2431-2434.	3.3	10
11	Impact of next generation sequencing results on clinical management in patients with hematological disorders. <i>Leukemia and Lymphoma</i> , 2021, 62, 1702-1710.	0.6	4
12	A Novel Machine Learning-Derived Molecular Classification Scheme with Prognostic Significance. <i>Blood</i> , 2021, 138, 3666-3666.	0.6	1
13	A Novel Approach to Induce ATRA Mediated Differentiation in NPM1 Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 786-786.	0.6	0
14	Descriptive comparison of hospital formulary decisions with published oncology valuation methods. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 891-905.	0.5	0
15	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. <i>Leukemia</i> , 2020, 34, 957-962.	3.3	32
16	Leukemia evolving from paroxysmal nocturnal hemoglobinuria. <i>Leukemia</i> , 2020, 34, 327-330.	3.3	3
17	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , 2020, 105, e98-e101.	1.7	23
18	Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria. <i>Leukemia and Lymphoma</i> , 2020, 61, 1242-1245.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. <i>British Journal of Haematology</i> , 2020, 188, 924-929.	1.2	15
20	Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 70-77.	0.2	10
21	Emerging treatment options for patients with high-risk myelodysplastic syndrome. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072095500.	1.1	19
22	Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101191.	0.7	6
23	Inherited Thrombocytopenia Caused by Germline <i>ANKRD26</i> Mutation Should Be Considered in Young Patients With Suspected Myelodysplastic Syndrome. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2020, 8, 232470962093894.	0.3	6
24	Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia. <i>Scientific Reports</i> , 2020, 10, 10325.	1.6	15
25	Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. <i>Leukemia Research</i> , 2020, 91, 106339.	0.4	20
26	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2020, 189, 318-322.	1.2	10
27	Distinctive and common features of moderate aplastic anaemia. <i>British Journal of Haematology</i> , 2020, 189, 967-975.	1.2	10
28	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2020, 61, 1943-1953.	0.6	2
29	The Clonal Trajectories of <i>SF3B1</i> Mutations in Myeloid Neoplasia. <i>Blood</i> , 2020, 136, 8-8.	0.6	1
30	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. <i>Blood</i> , 2020, 136, 2-2.	0.6	1
31	Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels. <i>Blood</i> , 2020, 136, 29-30.	0.6	4
32	Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia. <i>Blood</i> , 2020, 136, 1-1.	0.6	1
33	A Multi-Center Open-Labeled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory <i>IDH2</i> mutant AML. <i>Blood</i> , 2020, 136, 28-29.	0.6	0
34	Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles. <i>Blood</i> , 2020, 136, 25-25.	0.6	0
35	The Genomic Landscape of Wilms' Tumor 1 (<i>WT1</i>) Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 28-28.	0.6	1
36	Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia. <i>Blood</i> , 2020, 136, 34-35.	0.6	0

#	ARTICLE	IF	CITATIONS
37	A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 13-14.	0.6	2
38	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. <i>Blood</i> , 2020, 136, 21-21.	0.6	0
39	Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2020, 136, 21-21.	0.6	1
40	The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine. <i>Leukemia</i> , 2019, 33, 2971-2974.	3.3	32
41	Clonal Myeloid Events Drive Leukemic Evolution in Antecedent Hematologic Disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S337.	0.2	0
42	The Road Less Travelled, from Large Granular Lymphocytic Leukemia to Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S345.	0.2	0
43	A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 4231-4237.	3.2	30
44	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. <i>Blood Advances</i> , 2019, 3, 4228-4237.	2.5	34
45	When should transplant physicians think about familial blood cancers?. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e68.	0.6	4
46	Primer on Hereditary Cancer Predisposition Genes Included Within Somatic Next-Generation Sequencing Panels. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	6
47	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 673-673.	0.6	66
48	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2696-2696.	0.6	1
49	FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults. <i>Blood</i> , 2019, 134, 452-452.	0.6	2
50	The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy. <i>Blood</i> , 2019, 134, 16-16.	0.6	2
51	Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1507-1507.	0.8	3
52	CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q). <i>Blood</i> , 2019, 134, 1281-1281.	0.6	0
53	Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacitidine. <i>Blood</i> , 2019, 134, 537-537.	0.6	0
54	Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS. <i>Blood</i> , 2019, 134, 881-881.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia. <i>Blood</i> , 2019, 134, 564-564.	0.6	0
56	Molecular Characterization of EP300 Mutant Myeloid Neoplasia. <i>Blood</i> , 2019, 134, 5043-5043.	0.6	0
57	Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1226-1226.	0.6	0
58	Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential. <i>Blood</i> , 2019, 134, 3743-3743.	0.6	0
59	Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?. <i>Blood</i> , 2019, 134, 381-381.	0.6	2
60	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. <i>Blood</i> , 2019, 134, 2595-2595.	0.6	1
61	Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2553-2553.	0.6	2
62	<i>IDH1/2</i> Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by <i>IDH1/2</i> -Mutant Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 1705-1715.	3.2	80
63	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. <i>Blood Cancer Journal</i> , 2018, 8, 4.	2.8	43
64	Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. <i>Leukemia and Lymphoma</i> , 2018, 59, 363-371.	0.6	4
65	Improving Overall Survival in Older Adults With Acute Myeloid Leukemia: Subpopulations Matter. <i>Journal of Clinical Oncology</i> , 2018, 36, 3186-3188.	0.8	1
66	Reply to A. Piccardo et al, E. HindiÃ© et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 1889-1892.	0.8	3
67	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1831-1839.	0.8	112
68	TP53 Mutations in Myeloid Neoplasms and Clonal Hematopoiesis of Indeterminate Potential following Cytotoxic Therapy for Antecedent Malignancy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S264.	0.2	0
69	Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S261.	0.2	0
70	Mutational Landscape of Therapy-Related Myeloid Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S263-S264.	0.2	1
71	Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2018, 59, 755-757.	0.6	6
72	Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. <i>Journal of Clinical Investigation</i> , 2018, 128, 4260-4279.	3.9	97

#	ARTICLE	IF	CITATIONS
73	LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes. Blood, 2018, 132, 3073-3073.	0.6	2
74	Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes. Blood, 2018, 132, 1797-1797.	0.6	5
75	Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. Blood, 2018, 132, 4806-4806.	0.6	1
76	Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy. Blood, 2018, 132, 1389-1389.	0.6	1
77	Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential. Blood, 2018, 132, 3084-3084.	0.6	1
78	Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs).. Journal of Clinical Oncology, 2018, 36, 7031-7031.	0.8	2
79	Abstract 1501: Developing novel strategy for the treatment of acute myeloid leukemia by targeting retinoic acid signaling pathways. , 2018, , .		0
80	TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer. Blood, 2018, 132, 2270-2270.	0.6	0
81	Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype. Blood, 2018, 132, 2809-2809.	0.6	0
82	BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden. Blood, 2018, 132, 4352-4352.	0.6	1
83	Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia. Blood, 2018, 132, 2590-2590.	0.6	0
84	Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2018, 132, 2583-2583.	0.6	0
85	Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML. Blood, 2018, 132, 4353-4353.	0.6	0
86	Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?. Blood, 2018, 132, 900-900.	0.6	0
87	Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations. Blood, 2018, 132, 4389-4389.	0.6	1
88	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. Blood, 2018, 132, 2075-2075.	0.6	0
89	Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Blood, 2018, 132, 4603-4603.	0.6	0
90	Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia. Blood, 2018, 132, 4067-4067.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies. <i>Blood</i> , 2018, 132, 211-211.	0.6	0
92	Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS. <i>Blood</i> , 2018, 132, 3074-3074.	0.6	0
93	Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States. <i>Blood</i> , 2018, 132, 2298-2298.	0.6	1
94	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1527-1527.	0.6	0
95	Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. <i>Blood</i> , 2018, 132, 371-371.	0.6	0
96	Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia. <i>Blood</i> , 2018, 132, 3869-3869.	0.6	0
97	Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis. <i>Blood</i> , 2018, 132, 4805-4805.	0.6	0
98	Molecular features of early onset adult myelodysplastic syndrome. <i>Haematologica</i> , 2017, 102, 1028-1034.	1.7	20
99	Hemophagocytic Lymphohistiocytosis in a Patient With Hodgkin lymphoma and Concurrent EBV, CMV, and Candida Infections. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961668451.	0.3	9
100	Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 60-87.	2.3	254
101	Emerging therapies for acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 93.	6.9	119
102	Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 183-198.	3.3	32
103	Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature. <i>Leukemia Research</i> , 2017, 61, 25-32.	0.4	12
104	A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. <i>British Journal of Haematology</i> , 2017, 176, 241-247.	1.2	23
105	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 697-706.	3.2	56
106	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 899-907.	3.2	37
107	Hospital readmission rate for febrile neutropenia (FN) following high dose cytarabine (HiDAC) consolidation chemotherapy for acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2017, 35, e18513-e18513.	0.8	0
108	The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy. <i>Blood</i> , 2017, 130, 878-878.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure. Hematology American Society of Hematology Education Program, 2016, 2016, 470-477.	0.9	12
110	Primary Care Physician Preferences and Perspectives on Long-Term Care of Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S85-S86.	2.0	3
111	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. Blood, 2016, 128, 1659-1659.	0.6	2
112	Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes. Blood, 2016, 128, 2002-2002.	0.6	1
113	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). Blood, 2016, 128, 215-215.	0.6	25
114	Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy. Blood, 2016, 128, 2786-2786.	0.6	2
115	U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts. Blood, 2016, 128, 3155-3155.	0.6	5
116	Pathogenic Relevance of Germ Line TET2 Alterations. Blood, 2016, 128, 3160-3160.	0.6	2
117	Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag. Blood, 2016, 128, 3892-3892.	0.6	2
118	Analysis of Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated in Randomized Clinical Trials. Blood, 2016, 128, 4000-4000.	0.6	2
119	Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 4245-4245.	0.6	9
120	Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. Blood, 2016, 128, 4301-4301.	0.6	2
121	Clinical Effects of IDH1/2-Mutant Inhibitors in IDH1/2-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Suggestions from Ex Vivo Experiments. Blood, 2016, 128, 4308-4308.	0.6	1
122	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy. Blood, 2016, 128, 447-447.	0.6	3
123	Incorporation of Molecular Data into the Current Prognostic Models in Treated Patients with Myelodysplastic Syndromes: Which Model Is the Best. Blood, 2016, 128, 50-50.	0.6	5
124	Thirty-year analysis of randomized clinical trials in patients with acute myeloid leukemia.. Journal of Clinical Oncology, 2016, 34, 7032-7032.	0.8	0
125	Aldehyde Dehydrogenase Activity in the Leukemic Stem Cell Compartment Uncovers Opposing Methylation Patterns of Leukemia Stem Cells in AML. Blood, 2016, 128, 3925-3925.	0.6	0
126	Germline Variants of RUNX-1 in Myeloid Malignancy. Blood, 2016, 128, 3926-3926.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Targeting Autophagy in Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 4295-4295.	0.6	1
128	A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 4065-4065.	0.6	0
129	UTX mutations in Myeloid Neoplasms. <i>Blood</i> , 2016, 128, 3148-3148.	0.6	0
130	Distinct Clinical and Biological Implications of Various DNTMT3A Mutations in Myeloid Neoplasms. <i>Blood</i> , 2016, 128, 2872-2872.	0.6	0
131	Molecular and Clinical Characterization of Patients with Myeloid Neoplasms Carrying the 12p Deletion. <i>Blood</i> , 2016, 128, 2007-2007.	0.6	5
132	Phenotype/Genotype Associations in TET2-Driven Myeloid Neoplasms. <i>Blood</i> , 2016, 128, 4313-4313.	0.6	0
133	BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes. <i>Blood</i> , 2016, 128, 4293-4293.	0.6	0
134	Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response. <i>Blood</i> , 2016, 128, 1603-1603.	0.6	0
135	Rationale for Therapy Discontinuation in Patients with Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 3541-3541.	0.6	0
136	Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations. <i>Blood</i> , 2016, 128, 957-957.	0.6	0
137	Next-Generation Sequencing Analysis of Clonal Hierarchy and Dynamics in T-Large Granular Lymphocyte Leukemia Suggests Emergence of STAT3 Clones within Pre-Existing Dominant T-Cell Repertoire Responses Otherwise Silenced in Normal Individuals. <i>Blood</i> , 2016, 128, 2731-2731.	0.6	0
138	A Novel Prognostic Model for Risk Stratification in Younger Patients with Intermediate Risk Acute Myeloid Leukemia (AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S195-S196.	0.2	0
139	Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. <i>Haematologica</i> , 2015, 100, e434-e437.	1.7	27
140	The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine. <i>Clinical Cancer Research</i> , 2015, 21, 439-447.	3.2	37
141	Real-Life Experience of a Brief Arsenic Trioxide-Based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 292-297.	0.2	9
142	Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy. <i>Blood</i> , 2015, 126, 1319-1319.	0.6	2
143	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias. <i>Blood</i> , 2015, 126, 1361-1361.	0.6	2
144	Elevated Basal Autophagy in SF3B1 Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications. <i>Blood</i> , 2015, 126, 1647-1647.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC). <i>Blood</i> , 2015, 126, 1697-1697.	0.6	2
146	Survival Outcomes of Leukemias and Myelodysplastic Syndromes Occurring As Second Cancers in the United States: A SEER Registry-Based Population Analysis. <i>Blood</i> , 2015, 126, 2507-2507.	0.6	2
147	Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia. <i>Blood</i> , 2015, 126, 300-300.	0.6	3
148	Ex Vivo Experiments Show That IDH1/2-Mutant Inhibitors Can be Safely Used As Adjuvants to Regular Chemotherapy in IDH1/2-Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3788-3788.	0.6	3
149	The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 607-607.	0.6	3
150	Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response. <i>Blood</i> , 2015, 126, 678-678.	0.6	6
151	APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11047-11047.	0.8	1
152	Abstract 5575: Obesity and genomic changes in patients with myelodysplastic syndromes. , 2015, , .		0
153	Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML. <i>Blood</i> , 2015, 126, 1350-1350.	0.6	1
154	Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy. <i>Blood</i> , 2015, 126, 1271-1271.	0.6	0
155	Results of a Phase 2 Trial of High Dose Lenalidomide Monotherapy in Patients with Relapsed/Refractory Higher-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia with Trilineage Dysplasia. <i>Blood</i> , 2015, 126, 2901-2901.	0.6	0
156	Whole-Exome Sequencing Identifies Germline IDH2 and IDH3 mutations That Predispose to Myeloid Neoplasms. <i>Blood</i> , 2015, 126, 1405-1405.	0.6	3
157	Next-Generation Bisulfite Sequencing of Aml Reveals Widespread Acquisition of Epigenetic Abnormalities in Leukemic Stem Cells That Are Stably Retained in More Mature Leukemic Cell Fractions. <i>Blood</i> , 2015, 126, 2429-2429.	0.6	0
158	Real World Outcomes of Less Well-Characterized Acute Leukemias: A Population-Based Survival Analysis Using SEER Registry (1973-2012). <i>Blood</i> , 2015, 126, 4491-4491.	0.6	0
159	Characterization of the Mutational Spectrum in Young Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 5218-5218.	0.6	0
160	The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 86-86.	0.6	0
161	Clinical Evaluation of Combined Epigenetic Therapies on the Induction of Fetal Hemoglobin in Patients with Hematologic Malignancies. <i>Blood</i> , 2015, 126, 960-960.	0.6	0
162	Prognostic Impact of Molecular Mutations in AML at First Relapse. <i>Blood</i> , 2015, 126, 3825-3825.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 611-611.	0.6	0
164	Impact of Red Blood Cell and Platelet Transfusions in Acute Myeloid Leukemia (AML) Patients Undergoing Remission Induction Chemotherapy. <i>Blood</i> , 2015, 126, 2127-2127.	0.6	1
165	HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 314-318.	2.0	103
166	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. <i>Blood</i> , 2014, 124, 385-392.	0.6	195
167	A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. <i>Haematologica</i> , 2014, 99, 672-678.	1.7	48
168	The Impact of Clonal Architecture of IDH1 and IDH2 Mutant Cases on the Biology of Myeloid Malignancies. <i>Blood</i> , 2014, 124, 1897-1897.	0.6	1
169	Risk of hematologic malignancies following radiation treatment for well-differentiated thyroid cancer in the United States over 37 years.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6633-6633.	0.8	0
170	Different Genomic Patterns in Patients with Primary Acute Myeloid Leukemia (AML) Compared to Secondary AML in Patients with Normal Karyotype. <i>Blood</i> , 2014, 124, 1054-1054.	0.6	0
171	A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 168-168.	0.6	0
172	A Prognostic Scoring System for Newly Diagnosed Adult Acute Lymphocytic Leukemia Patients. <i>Blood</i> , 2014, 124, 5252-5252.	0.6	0
173	Differences in Genomic Patterns and Clinical Outcomes Between African-American and White Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 3274-3274.	0.6	4
174	Comparison of Very Low-Dose Decitabine to Standard-Dose Hypomethylating Agents in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 1933-1933.	0.6	0
175	Impact of Day 28 Absolute Lymphocyte Count on Outcome of Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 5256-5256.	0.6	1
176	The Novel Plk Inhibitor Volasertib Overcomes Cytarabine Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 979-979.	0.6	0
177	Assessing the Value of Echocardiograms for Patients with Acute Myeloid Leukemia (AML) Receiving Anthracyclines. <i>Blood</i> , 2014, 124, 1290-1290.	0.6	0
178	Time to Complete Remission As a Function of Kinetics of White Blood Cell Elimination and Recovery in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy. <i>Blood</i> , 2014, 124, 5266-5266.	0.6	0
179	Distinct Pattern of Genomic Changes Associated with Hypoplastic Compared to Hyper/Normoblastic Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 4603-4603.	0.6	0
180	Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy. <i>Blood</i> , 2014, 124, 3766-3766.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Hereditary Mutations Are Present As Pathogenic or Predisposition Factors in Otherwise Typical Adult MDS. <i>Blood</i> , 2014, 124, 3233-3233.	0.6	0
182	Multiple Mechanisms Leading to ARID2 defects in Myeloid Neoplasms. <i>Blood</i> , 2014, 124, 4610-4610.	0.6	0
183	Effect of Early Non-Hematologic Treatment Toxicity on Complete Remission (CR) and Time to CR in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy. <i>Blood</i> , 2014, 124, 2279-2279.	0.6	0
184	Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 483-490.	0.6	13
185	An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2013, 122, 2682-2682.	0.6	7
186	A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 1427-1427.	0.6	0
187	Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias. <i>Clinical Cancer Research</i> , 2012, 18, 6723-6731.	3.2	100
188	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. <i>Haematologica</i> , 2012, 97, 1736-1742.	1.7	65
189	Acute Lymphoblastic Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 858-914.	2.3	60
190	The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. <i>Haematologica</i> , 2012, 97, 1225-1233.	1.7	19
191	Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. <i>Blood</i> , 2012, 119, 55-63.	0.6	23
192	Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. <i>British Journal of Haematology</i> , 2012, 158, 198-207.	1.2	7
193	Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide. <i>Clinical Cancer Research</i> , 2011, 17, 5473-5480.	3.2	440
194	Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. <i>Blood</i> , 2011, 117, 3302-3310.	0.6	77
195	Enzymatic Incorporation of Multiple Dyes for Increased Sensitivity in QD-FRET Sensing for DNA Methylation Detection. <i>ChemBioChem</i> , 2010, 11, 71-74.	1.3	33
196	Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents. <i>Current Opinion in Hematology</i> , 2010, 17, 104-109.	1.2	7
197	Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. <i>Leukemia Research</i> , 2010, 34, 877-882.	0.4	78
198	Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. <i>Leukemia and Lymphoma</i> , 2010, 51, 1711-1719.	0.6	72

#	ARTICLE	IF	CITATIONS
199	Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. <i>Epigenetics</i> , 2010, 5, 590-600.	1.3	42
200	DNA methylation detection using MS-qFRET, a quantum dot-based nanoassay. <i>Methods</i> , 2010, 52, 237-241.	1.9	34
201	Statistically Significant Differences In Toxicities Between L- and PEG Asparaginase In Adult Patients with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 2121-2121.	0.6	1
202	Abstract 3906: Twist regulates estrogen receptor expression in breast cancer. , 2010, , .		0
203	Relevance of Minor PIG-A Mutations In Acquired Aplastic Anemia and Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 4433-4433.	0.6	0
204	MS-qFRET: A quantum dot-based method for analysis of DNA methylation. <i>Genome Research</i> , 2009, 19, 1455-1461.	2.4	126
205	Progressive Chromatin Repression and Promoter Methylation of <i>CTNNA1</i> Associated with Advanced Myeloid Malignancies. <i>Cancer Research</i> , 2009, 69, 8482-8490.	0.4	46
206	Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 315-325.	1.1	8
207	Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. <i>Blood</i> , 2009, 114, 2764-2773.	0.6	259
208	MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. <i>Blood</i> , 2009, 114, 3448-3458.	0.6	292
209	A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group) Tj ETQq1 1 0.784314 rgrBT /Overlo	1.0	14
210	Promoter methylation of <i>HIN-1</i> in the progression to esophageal squamous cancer. <i>Epigenetics</i> , 2008, 3, 336-341.	1.3	43
211	Tamoxifen-stimulated growth of breast cancer due to p21 loss. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 288-293.	3.3	86
212	Addition of Histone Deacetylase Inhibitors in Combination Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 1955-1956.	0.8	27
213	A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. <i>Blood</i> , 2007, 110, 1762-1769.	0.6	84
214	DNA Demethylating Agents and Histone Deacetylase Inhibitors in Hematologic Malignancies. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 40-48.	1.0	31
215	Monitoring Methylation and Gene Expression in Cancer. , 2007, 383, 187-202.		1
216	Modulating Gene Expression as a Therapeutic Approach in the Treatment of AML. , 2007, , 275-291.		0

#	ARTICLE	IF	CITATIONS
217	Myelodysplastic Syndrome (MDS) Displays Profound and Functionally Significant Epigenetic Deregulation Compared to Acute Myeloid Leukemia (AML) and Normal Bone Marrow Cells.. Blood, 2007, 110, 345-345.	0.6	2
218	a-catenin Hypermethylation Correlates with AML Transformation in Patients with and without 5q Defects.. Blood, 2007, 110, 2119-2119.	0.6	0
219	LKB1 Protein Expression in Human Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2006, 14, 146-153.	0.6	51
220	Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms. Cancer Research, 2006, 66, 6361-6369.	0.4	470
221	Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacididine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.. Blood, 2006, 108, 517-517.	0.6	17
222	Hypermethylation of a Small CpGuanine-Rich Region Correlates with Loss of Activator Protein-2± Expression during Progression of Breast Cancer. Cancer Research, 2004, 64, 1611-1620.	0.4	67
223	New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Research, 2004, 6, 219-24.	2.2	83
224	Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer. Cancer Treatment Reviews, 2004, 30, 303-307.	3.4	2
225	Plasma cell dyscrasia, Hodgkin lymphoma, HIV, and Kaposi sarcoma-associated herpesvirus. Current Opinion in Oncology, 2002, 14, 543-545.	1.1	9